Our group has earlier demonstrated that three enzymes sensitive to peptidase inhibitors (PIs), amastatin (A)-, captopril (C)-, and phosphoramidon (P), played an important role in inactivation of enkephalins at the spinal level. Dynorphin-converting enzyme (DCE) hydrolyzes dynorphin (Dyn) A (1-17) or Dyn A (1-13) mainly at the Arg 6 -Arg 7 bond. Dynorphin A and its derived peptides interact with opioid and glutamate receptors at their N-and C-terminals, respectively. The purpose of the present study was to evaluate the antinociceptive potency and toxicity of intrathecal administered Dyn A (1-17), Dyn A (1-13), or Dyn A (1-6) under pretreatment with ACP and/or the DCE inhibitor p-hydroxymercuribenzoate (PHMB). The effect of these PIs on Dyn A (1-17)-induced inhibition of electrically-evoked contractions in mouse vas deferens was also investigated. The inhibitory potency of Dyn A (1-17) on electrically-evoked contractions in mouse vas deferens under pretreatment with ACP was higher than that with AC, AP, or CP. Pretreatment with ACP augmented Dyn A (1-17) or (1-13)-induced antinociception by approximately 50-or 30-fold with no sign of allodynia when administered intrathecally at low doses. Pretreatment with ACP and PHMB induced neuropathy. These findings showed that intrathecal administration of low-dose Dyn A (1-17) or DynA (1-13) increased antinociception under pretreatment with ACP, but without signs of allodynia in rat.
Introduction
Dynorphin (Dyn) A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) and (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) interacts with both opioid and N-methyl-D-aspartate (NMDA) receptors: their N-terminals activate the former with high affinity, while its C-terminals activate the latter with low affinity [1] [2] [3] [4] .
In fact, intrathecal (i.t.) low dose (0.5 -2 nmol) administration of Dyn A induced an antinociceptive effect [5] [6] , whereas that at a high dose induced longlasting mechanical allodynia and motor dysfunction [7] [8] [9] [10] .
Three peptidases, an aminopeptidase N (APN), a dipeptidylcarboxypeptidase, and neutral endopeptidase-24.11 (NEP), play an important role in degradation of opioid peptides. High-performance liquid chromatography revealed that [Leu 5 ]-enkephalin (LE) [11] or Dyn A (1-8) [12] remained intact in the presence of a mixture of peptidase inhibitors (PIs) when incubated with membrane preparation, but was completely hydrolyzed after incubation in their absence.
Preparations isolated in vitro allow a drug to be quantified and its efficacy, potency, and affinity compared more accurately than can be done with in vivo methods [13] . Earlier research on the inhibitory potency of LE or Dyn A (1) (2) (3) (4) (5) (6) (7) (8) against electrically-evoked contractions in mouse vas deferens (MVD) demonstrated that it was enhanced by exposure to various combinations of amastatin (A), captopril (C), and phosphoramidon (P) [14] [15] . These results correspond (1-17)-induced antinociception by more than 500- [14] , 100- [16] , and 30-fold [17] , respectively.
Dynorphin-converting enzyme (DCE) hydrolyzes Dyn A mainly at the Arg 6 -Arg 7 bond, resulting in the production of N-and C-terminal region peptide fragments, and this enzyme is not inhibited by ACP [18] . Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF-MS) identified N-terminal peptide fragment Dyn A (1-6) from Dyn A (1-17), but not the corresponding C-terminal peptide fragment, Dyn A (7-17), after incubation of Dyn A (1-17) with membrane fraction from rat midbrain or caudate putamen under pretreatment with ACP [17] [19] . These results suggest that C-terminal peptide fragments such as DynA (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) are catabolized, generating shorter, extremely weak, non-toxic products, particularly under pretreatment with ACP [17] . The purpose of the present study was to evaluate antinociceptive potency and toxicity with i.t. administration of Dyn A (1-17), Dyn A (1-13), or Dyn A (1-6) under pretreatment with ACP and/or DCE inhibitor p-hydroxymercuribenzoate (PHMB) in rat spinal cord under physiological conditions. In an attempt to further characterize the pharmacological action of PIs, the effect of ACP on Dyn A (1-17)-induced inhibition of electrically-evoked contractions in MVD was also evaluated.
Materials and Methods
The present animal experiments were performed in strict accordance with the guidelines (http://www.u-tokai.ac.jp/about/concept/guidance.html) of Tokai Uni-versity and with the approval of the Animal Investigation Committee of this institute.
Chemicals
Dynorphin A (1-17), Dyn A (1-13), A, and P were purchased from Peptide Institute Inc. (Minoh, Japan). Dyn A (1-6) was purchased from Phoenix Pharmaceuticals, Inc. (Mannheim, Germany). Captopril, D-Phe-Cys-Tyr-D-Trp-OrnThr-Pen-Thr-NH 2 (CTOP, a μ-opioid receptor antagonist), nor-binaltorphiminedihydrochloride (nor-BNI, a κ-opioid receptor antagonist), and naltrindole hydrochloride (NTI, a δ-opioid receptor antagonist) were purchased from SIGMA Japan (Tokyo, Japan). Naloxone hydrochloride (NOX, a non-selective opioid receptor antagonist) was purchased from Daiichi-Sankyo Company, Limited (Tokyo, Japan). P-hydroxymercuribenzoate was purchased from Merck Japan (Tokyo, Japan). All chemicals apart from nor-BNI, NTI, and PHMB were dissolved in saline. Nor-BNI and NTI were dissolved in water. The PHMB was dissolved in saline with 0.1 N-NaOH up to a pH of 9.0. The solution for all drugs used was prepared to the desired concentration just before use. In accordance with the method of earlier studies, CTOP (3 nmol, i. 
In Vitro Isolated Preparations
Male ICR JCL mice (30 -40 g each; Nihon Clea, Tokyo, Japan) were used. Mouse vas deferens was harvested and prepared for electrical stimulation as described previously [24] . The percent (%) inhibition of stimulated muscle twitch produced by each opioid was plotted against its log concentration to determine the IC 50 (concentration required to produce 50% inhibition of the twitch). When investigating the effect of PIs on Dyn A (1-17)-induced inhibition of contractions, a period of 3 min was given before administration of Dyn A (1-17). The % difference shown in the tables was calculated as follows: % difference = [(IC 50 before each treatment − IC 50 after each treatment)/IC 50 before each treatment] × 100 [24] .
Intrathecal Administration
Intrathecal catheters were implanted in Male Wistar rats (180 -220 g each; Nihon Clea, Tokyo, Japan) under inhalation anesthesia with nitrous oxide, oxygen, and isoflurane (2%) as described previously [17] [25] . After surgery, all rats were housed individually in a temperature-and light-controlled environment with free access to food and water. Only rats with normal motor function and behavior were used for the experiments 7 days later. Drugs were injected at a volume of 10 μl followed by 10 μl saline over 1 min.
Tail-Flick Test
The investigators were blind to all drug treatments carried out in these experiments. Induction of antinociception by Dyn A (1-17), Dyn A (1-13), or Dyn A (1-6) was measured by the tail immersion assay, with 55˚C as the nociceptive stimulus [26] [27] . The latency to flick the tail was measured as described previously [17] . A cut-off time of 5 sec was used to prevent any injury to the tail. The % of maximal possible effect (MPE) for each animal at each time was calculated using the following formula: %MPE = [(test latency − baseline latency)/(5 − baseline latency)] × 100. The area under the curve (AUC) value for the antinociceptive action of each drug was also calculated in some of the experiments.
Von Frey Test
The threshold for tactile allodynia was measured with a series of von Frey filaments (von Frey Filaments; Bioseb, Vitrolles, France), ranging from 2.44 to 5.88 (0.03 -60.0 g), according to the methods of Park et al. [28] and Zhu et al. [29] .
The rats were placed in individual transparent plastic boxes with a wire mesh floor at least 15 min before testing began to allow acclimatization to the environment. The filaments were pushed against the plantar surface of the right hind paw. Tactile thresholds were measured at intervals before and after administration of drugs. Results were reported as the mean value of 4 readings from the right hind paw in each rat. 
Animal Experimental Protocol

Combination of Dyn A (1-17) and PHMB Together with ACP
Ten minutes following i.t. administration of PHMB and ACP, Dyn A (1-17) (0.3 nmol) was administered intrathecally. To determine whether the antinociceptive effect of Dyn A (1-17) was increased by joint administration of PHMB and ACP, the rats were tested in the following groups: Group 1, Dyn A (1-17) alone; Group 2, Dyn A (1-17) with ACP; Group 3, Dyn A (1-17) with PHMB; and Group 4, Dyn A (1-17) in combination PHMB and ACP.
Selective or Non-Selective Opioid Receptor Antagonists
To investigate the effect of opioid receptor antagonists on Dyn A (1-17) (0.3 nmol) or DynA (1-13) (0.3 nmol)-induced antinociception under pretreatment with ACP, NOX (1 mg/kg, subcutaneously), CTOP (3 nmol, i.t.) [22] , NTI (66 nmol, i.t.) [21] , and nor-BNI (20 mg/kg, subcutaneously) [23] were injected at 20 min, 15 min, 30 min, and 24 hr, respectively, before i.t. administration of Dyn A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) or Dyn A (1-13).
Statistical Analyses
The results are given as the mean and standard error of the mean (S.E.M.) of the data. The statistical analysis was conducted using computer software (Prism, version 6.0 c, Graph Pad Software, San Diego, CA, USA) for a comparison across experimental conditions. When a significant difference among the %MPE data after drug administration was obtained in a two-way (drugs and time) repeated measures analysis of variance (ANOVA), Dunn's multiple comparison test was applied to determine the significance at each time point. When a significant difference was observed in the AUC data among the groups in a two-way (drugs and dose) repeated ANOVA, Dunn's multiple comparison test was applied to determine the significance at each dose. When a significant difference within groups was obtained in the Kruskal-Wallis test, Dunn's comparison test was applied to determine significance.
Results
Enhanced Effect of PIs in Paired Combinations or all Together on Dyn A (1-17)-Induced Inhibition in Isolated Preparation
The results showed that Dyn A (1-17) significantly inhibited electrically-evoked contractions in MVD. The inhibitory potency of Dyn A (1-17) was dose-dependently augmented by ACP ( Table 1) with ACP than with CP; it was also stronger than with administration of AP or AC, but not significantly so ( Table 2) . 
Effect of ACP on Dyn A (1-17)-or Dyn A (1-13)-Induced Antinociception
Change value for %MPE similar to that with 5 nmol Dyn A (1-17) alone (Figure 3(b) ).
The onset, offset, and duration of the antinociceptive effect induced by i.t. administration of 0.3 nmol Dyn A (1-13) under pretreatment with ACP was similar to that with 10 nmol Dyn A (1-13) alone (Figure 3(c) ). Administration of 0.3 nmol Dyn A (1-13) under pretreatment with ACP yielded an AUC 0-120min value for %MPE similar to that with 10 nmol Dyn A (1-13) alone (Figure 3(d) ).
Intrathecal administration of Dyn A (1-17) under pretreatment with ACP induced a 50-fold increase in the antinociceptive effect on the tail-flick response, while that of Dyn A (1-13) increased it 30-fold. (Figure 4(c) ).
Effect of ACP on Dyn A (1-6)-Induced Antinociception
Effect of Antagonists on Dyn A (1-17)-or Dyn A (1-13)-Induced Antinociception under Pretreatment with ACP
The antinociceptive potency of Dyn A (1-17) or Dyn A (1-13) under pretreatment with ACP was significantly attenuated by NOX, CTOP, or nor-BNI; it was also was attenuated by NTI, but not significantly so ( Figure 5 and Figure 6 ).
Effect of PHMB on Dyn A (1-17)-Induced Antinociception
The antinociceptive potency of 0.3 nmol Dyn A (1-17) under pretreatment with ACP was significantly higher than that of 0. 
ACP Attenuates Allodynia Induced by i.t. Administration of Dyn A (1-17)
No significant differences were observed in the baseline threshold stimulus be- 
Discussion
The present results revealed that the antinociceptive potency of Dyn A (1-17), Dyn A (1-13), or Dyn A (1-6) depended on the dose and length of the peptide when administered i.t. in the absence of, or under pretreatment with, ACP. This is in good agreement with the results of earlier studies showing that Dyn A (1-17)-induced antinociception at the supraspinal level was greater than that of Dyn A (1-6) or Dyn A (1-13) at the same dose [17] , and that Dyn A (1-17) had a greater analgesic effect than Dyn A (1-13) in the absence of ACP [30] . Pretreatment with ACP increased antinociception with low-dose Dyn A (1-17), with neither hyperalgesia nor paralysis. The present findings then provide further support for the view that C-terminal peptide fragments of Dyn A (1-17), such as Dyn A (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , are catabolized into shorter products that are extremely weak toxicity under pretreatment with ACP [17] , thus reducing neuropathic symptoms. Intrathecal administration of Dyn A (1-17) and LE [31] under pretreatment with ACP augmented antinociception by at least 50-and 100-fold, respectively. [35] . Taken together, this suggests that this co-localization of peptidases and opioid peptides plays a critical role in nociception through the latter's inactivation in the spinal cord.
Pretreatment of paired combinations (2 µM each of AP, AC, or CP) or all three PIs together (2 µM ACP) revealed that AP or ACP significantly increased Dyn A (1-17)-induced inhibition of electrically-evoked contractions in MVD. This effect was significantly stronger with ACP than with AC or CP; it was also stronger than with administration of AP, but not significantly so. These results demonstrate that ACP is required to inhibit degradation of intact Dyn A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , and that any residual pair of peptidases inactivates substantial amounts of Dyn A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . This is in good agreement with the results of an earlier study by this group demonstrating that the antinociceptive potency of Dyn A (1-17) was Both the present and earlier studies demonstrated that LE (IC 50 : 1.74 nM) [36] showed greater potency than Dyn A (1-17) (IC 50 : 4.53 nM) under pretreatment with ACP in isolated MVD preparation. On the other hand, Dyn A (1-17) (ED 50 : 0.272 nmol) showed greater potency than LE (ED 50 : 4.5 nmol) [31] under pretreatment with ACP in the tail flick test. This discrepancy might be explained by differences in the opioid receptor subtype mainly responsible for each effect between isolated MVD preparation and spinal cord. The inhibitory potency of the δ-opioid receptor agonist in isolated MVD preparation is greater than that of the others [37] . [Leu 5 ]-enkephalin [38] and Dyn A [1] [39] mainly bind to δ-and κ-opioid receptors, respectively, so the inhibitory potency of LE in isolated MVD preparation is greater than that of Dyn A (1-17) . In contrast, the present and earlier [31] studies using opioid receptor selective antagonists showed that i.t. 
Conclusion
In conclusion, the present results showed that inactivation of A-, C-, or P-sen- 
